Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus UROVIST MEGLUMINE DIU CT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus UROVIST MEGLUMINE DIU CT.
CONRAY 43 vs UROVIST MEGLUMINE DIU/CT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Urovist Meglumine DIU/CT is a contrast agent containing meglumine diatrizoate, an ionic monomeric iodinated radiopaque medium. It attenuates X-rays, enhancing vascular and tissue contrast during imaging. The diatrizoate ion increases plasma osmolality, potentially causing vasodilation and hemodynamic effects.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Intravenous administration: 100-200 mL of a 30% solution (containing 30% meglumine diatrizoate) infused over 10-30 minutes for CT imaging. Repeated doses may be given up to a maximum total dose equivalent to 4.0 mL/kg.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life 1–2 hours in patients with normal renal function. Prolonged to >20 hours with severe renal impairment (CrCl <30 mL/min).
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Renal: >95% unchanged within 24 hours by glomerular filtration. Biliary/fecal: <5%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent